Discussion
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel continues to show potential to control motor symptoms in people with Parkinson’s disease, with the benefits of a single dose sustained for up to three years in a small Phase 1 trial. These findings from the Phase 1 exPDite study (NCT04802733),…
